Search
Returning search results with filters:
Remove filter for
Last updated: January 2022
Remove filter for
Last updated: 2022
Remove filter for
Type: Alert
Clear all
Type
Audience
Category
Issue
Last updated
Please note: using the search filters may not provide accurate search results for records prior to November 2021. When searching for older records, please ensure that you use the include archived checkbox.
Displaying 1 - 6 of 6 items.
Lichtenberg generators pose life-threatening danger to users
Health Canada is aware of six reports of fatal injuries in Canada since 2017 resulting from the use of wood-burning devices know as Lichtenberg generators. This information was reported from provincial and territorial electrical safety authorities.…
AlertPublic advisory | 2022-01-19
PAXLOVID (nirmatrelvir and ritonavir) - Dosing and Dispensing in Renal Impairment, Risk of Serious Adverse Reactions Due to Drug Interactions, and English-Only Labels
UPDATED INFORMATION - July 6, 2022
A new PAXLOVID dose pack for use in patients with moderate renal impairment (eGFR ≥30 to <60 mL/min) is now available with a distinct DIN: 02527804. Pfizer has introduced this new packaging configuration to…
AlertHealth professional risk communication | 2022-01-17
Health Canada safety review finds link between the use of Xeljanz and Xeljanz XR (tofacitinib) and increased risk of serious heart-related issues and cancer
UPDATE - January 12, 2022: Safety Review found a link between the use of Xeljanz/Xeljanz XR (tofacitinib) and the risks of serious heart-related problems and cancer
Health Canada completed a safety review that confirmed a link between the use of…
AlertPublic advisory | 2022-01-12
XELJANZ/XELJANZ XR (tofacitinib) – Risk of Major Adverse Cardiovascular Events, Malignancy, Thrombosis and Infection
A post-authorization safety study in RA patients 50 years of age or older with at least one additional CV risk factor showed an increased risk of MACE and malignancy in patients treated with XELJANZ (5 mg BID or 10 mg BID) in comparison to TNFi. An…
AlertHealth professional risk communication | 2022-01-12
Shelf Life Extension for the SPIKEVAX (elasomeran) COVID-19 Vaccine with Printed Expiry Dates on Vial and Carton Labels
On December 23, 2021, Health Canada authorized a shelf-life extension, from 7 months to 9 months, for SPIKEVAX / COVID-19 Vaccine Moderna 5 mL vials. This 2-month extension may be retroactively applied to vials that are currently on the market with…
AlertHealth professional risk communication | 2022-01-11
Casirivimab and Imdevimab – High Risk of Treatment Failure Due to Circulation of SARS-CoV-2 Omicron Variant
There is a high risk of treatment failure with the casirivimab and imdevimab combination based on analysis of neutralization activity against selected mutations of the SARS-CoV-2 Omicron variant. The Canadian Product Monograph for casirivimab and…
AlertHealth professional risk communication | 2022-01-07